Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
WBA Price Action
Last 7 days
-0.4%
Last 30 days
-2.0%
Last 90 days
-4.4%
Trailing 12 Months
-38.2%
WBA Stock Price
WBA RSI Chart
WBA Valuation
WBA Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
WBA Fundamentals
WBA Revenue
WBA Earnings
WBA Profitability
WBA Investor Care
The Good News
Walgreens Boots Alliance reported adjusted earnings that surpassed expectations, leading to a more than 5% increase in pre-market shares. Analysts, such as Charles Rhyee of TD Cowen, maintain a Buy rating with a target price of $16.00, citing potential improvements in store optimization and pharmacy negotiations. Additionally, there is institutional interest, with hedge funds holding over 58% of shares. (Sources: Business Insider Business Insider)
The Bad News
Walgreens Boots Alliance has seen its stock decline by over 65% this year, facing challenges from declining drug reimbursements and increased competition from companies like Amazon. The company reported a massive quarterly loss attributed to goodwill impairment charges and ongoing macroeconomic pressures, leading to downgrades from multiple analysts. The consensus rating remains largely negative, with many analysts recommending a sell or hold stance due to declining retail pharmacy sales and a tough consumer environment. (Sources: AOL Business Insider)
Revenue & Growth
Revenue Breakdown
As of: Nov 30, 2024
USRetail Pharmacy
| |||||||||||||||||||
| |||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 151.9B | 0 | 0 | 0 |
| 2024 | 144.6B | 145.5B | 147.7B | 150.4B |
| 2023 | 133.3B | 136.1B | 139.1B | 142.4B |
| 2022 | 135.9B | 134.5B | 132.7B | 132.2B |
| 2021 | 125.0B | 128.6B | 132.5B | 135.0B |
| 2020 | 129.8B | 125.6B | 122.0B | 123.5B |
| 2019 | 136.1B | 136.4B | 136.9B | 133.0B |
| 2018 | 124.0B | 128.2B | 131.5B | 134.6B |
| 2017 | 116.1B | 116.7B | 118.2B | 120.5B |
| 2016 | 116.5B | 117.2B | 117.4B | 116.8B |
| 2015 | 84.6B | 94.0B | 103.4B | 112.9B |
| 2014 | 74.3B | 75.3B | 76.4B | 77.6B |
| 2013 | 0 | 0 | 72.2B | 73.3B |
Get all data in R, Python etc through our Historical Stock Data APIs
Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. The company operates under the Walgreens and Duane Reade brands in the United States. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. The company operates retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
| CEO | Ms. Ginger L. Graham |
|---|---|
| WEBSITE | walgreensbootsalliance.com |
| SECTOR | Healthcare |
| INDUSTRY | Pharmaceutical Retailers |
| EMPLOYEES | 65535 |
